Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

SonoMYC Bringing MYC inhibition to the brain by ultrasound technology

Coordinator
Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio), Spain
Runs
1 October 2025 to 31 March 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101247187

What the project is doing

In the project's own words, from its summary on CORDIS.

Brain tumours and brain metastases pose a significant therapeutic challenge due to limited treatment options, fatally linked to high morbidity and mortality. Treatment of these cancers is hindered by the presence of the blood-brain barrier (BBB), that restricts the free passage of molecules larger than 400 daltons, reducing the effectiveness of therapeutically impermeable compounds. While deregulation of the MYC oncogene is a main feature of these cancers, to date, effective and clinically-viable, BBB-permeable MYC inhibitors are lacking.

This project proposes to combine Omomyc (OMO-103), developed in our laboratory and the best characterized, direct MYC inhibitor, with Carthera's SonoCloud technology, which temporarily disrupts the BBB using ultrasound. Omomyc is currently under clinical evaluation for other systemic aggressive cancers, under the sponsorship of Peptomyc, a spin-off from our lab, focusing on clinical application of our inhibitors. This new investigation will establish the feasibility and viability of its commercial development into a disruptive novel treatment for primary and metastatic brain tumours.

This combination aims to enhance OMO-103 delivery to the brain, to improve its therapeutic efficacy and reducing any potential systemic side effects. The synergy between these technologies has the potential to generate new intellectual properties, facilitate technology transfers, and address a growing market for brain tumour therapies. By overcoming the BBB challenge and directly targeting MYC, this approach could significantly impact brain cancer treatment and create new commercial opportunities.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio)BarcelonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI